
Sign up to save your podcasts
Or


🚨 Game-Changer in Lung Cancer! 🫁💉
The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯
✅ 65.4% 5-year OS vs. 55.0% with chemo alone
🧬 pCR = 95.3% survival
📉 ctDNA clearance = better outcomes
⚖️ Time to rethink neoadjuvant strategies
📚 Read in NEJM: A landmark in thoracic oncology!
#LungCancer #Immunotherapy #NSCLC #Nivolumab #Oncology #CancerResearch #PrecisionMedicine
By Dr RR Baliga, MD, MBA5
66 ratings
🚨 Game-Changer in Lung Cancer! 🫁💉
The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯
✅ 65.4% 5-year OS vs. 55.0% with chemo alone
🧬 pCR = 95.3% survival
📉 ctDNA clearance = better outcomes
⚖️ Time to rethink neoadjuvant strategies
📚 Read in NEJM: A landmark in thoracic oncology!
#LungCancer #Immunotherapy #NSCLC #Nivolumab #Oncology #CancerResearch #PrecisionMedicine

905 Listeners

3,381 Listeners

20,577 Listeners